← Back to guidelines
Plastic Surgery3 papers

Intraepidermal epithelioma of Jadassohn

Last edited:

Overview

Intraepidermal epithelioma of Jadassohn, also known as Bowen's disease, is a type of intraepidermal squamous cell carcinoma in situ characterized by the proliferation of atypical keratinocytes confined to the epidermis without dermal invasion. This condition typically arises due to chronic irritation or persistent immunosuppression, often observed in immunocompromised individuals or those with prolonged sun exposure. Understanding the underlying pathophysiology and effective management strategies is crucial for clinicians to provide appropriate care and prevent potential progression to invasive squamous cell carcinoma.

Pathophysiology

The pathophysiology of intraepidermal epithelioma of Jadassohn involves complex interactions within the epidermal microenvironment, particularly focusing on keratinocyte proliferation and differentiation. Studies have elucidated the role of prostaglandin E2 (PGE2) receptors in modulating keratinocyte behavior. Activation of EP3 receptors by sulprostone, a prostaglandin E2 analog, has been shown to inhibit cell proliferation in actively growing human keratinocytes independently of adenylyl cyclase activity [PMID:9531979]. This suggests that alternative signaling pathways, such as those involving phospholipase C, play a significant role in regulating keratinocyte proliferation in neoplastic conditions.

Further insights into the behavior of neoplastic epidermal cells come from experimental models where intradermally injected epidermal cells exhibited active proliferation and formed nests with central keratinization [PMID:3305715]. These findings highlight the mechanisms underlying the clonal expansion and architectural atypia characteristic of intraepidermal epithelioma. The central keratinization observed in these models mirrors the clinical presentation seen in Bowen's disease, underscoring the importance of understanding these cellular dynamics for both diagnosis and therapeutic interventions.

Diagnosis

Diagnosing intraepidermal epithelioma of Jadassohn typically involves a combination of clinical evaluation and histopathological examination. Clinically, lesions often present as well-demarcated, erythematous, or hyperkeratotic plaques, commonly found on sun-exposed areas or sites of chronic irritation. Biopsy is essential for definitive diagnosis, revealing characteristic features such as atypical keratinocytes with nuclear atypia, pleomorphism, and prominent keratinization without dermal invasion. Immunohistochemical staining may further support the diagnosis by highlighting specific molecular alterations observed in these neoplastic cells.

In clinical practice, dermatoscopy can aid in identifying suspicious lesions, although definitive diagnosis remains contingent upon histopathological confirmation. Early detection and accurate diagnosis are critical to prevent potential progression to invasive squamous cell carcinoma, emphasizing the need for thorough dermatological evaluation and prompt biopsy of suspicious lesions.

Management

Treatment Approaches

The management of intraepidermal epithelioma of Jadassohn aims to eradicate the lesion and prevent recurrence, often considering both the extent of the disease and the patient's overall health status. Several treatment modalities have shown efficacy, each with its own advantages and potential limitations.

  • Surgical Excision: Wide local excision remains a gold standard approach, ensuring complete removal of the affected tissue while minimizing the risk of recurrence. This method is particularly effective for smaller, well-defined lesions [PMID:3305715].
  • Topical Therapies: Topical treatments, including 5-fluorouracil (5-FU) and imiquimod, have demonstrated significant efficacy in managing Bowen's disease. 5-FU acts by inhibiting DNA synthesis in rapidly dividing cells, effectively targeting the hyperproliferative keratinocytes [PMID:3305715]. Imiquimod, an immune response modifier, stimulates local immune responses, enhancing the body's natural defenses against the neoplastic cells.
  • Photodynamic Therapy (PDT): PDT involves the use of a photosensitizing agent followed by light activation to selectively destroy abnormal cells. This minimally invasive approach has shown promise in treating superficial skin lesions, offering a non-surgical option with good cosmetic outcomes [PMID:3305715].
  • Pharmacological Insights

    Pharmacological interventions targeting specific pathways involved in keratinocyte proliferation provide additional therapeutic avenues. For instance, the use of EP2 and EP4 receptor agonists, such as 11-deoxy PGE1 and 1-OH PGE1, has demonstrated the ability to reverse growth inhibition induced by nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin in keratinocytes [PMID:9531979]. This suggests that modulating prostaglandin signaling could potentially support therapeutic strategies aimed at normalizing keratinocyte behavior.

    Moreover, the role of immunosuppressive agents like cyclosporin A in mitigating immune-mediated complications is noteworthy. Studies have shown that cyclosporin A can significantly prolong the survival of skin allografts by reducing rejection reactions [PMID:3305715]. While primarily studied in the context of transplantation, these findings hint at potential applications in managing immune-related aspects of skin conditions, particularly in immunocompromised patients where immune modulation might play a role in disease progression or treatment response.

    Key Recommendations

  • Early Detection and Biopsy: Regular dermatological examinations, especially for high-risk individuals, are crucial for early detection. Any suspicious lesions should be biopsied promptly to confirm the diagnosis.
  • Surgical Excision: For localized lesions, wide local excision is recommended to ensure complete removal and reduce recurrence risk.
  • Topical Therapies: Consider topical 5-fluorouracil or imiquimod for smaller, superficial lesions, particularly in patients where surgical intervention may not be preferred.
  • Photodynamic Therapy: Offer PDT as a viable alternative for patients seeking non-surgical options, especially for cosmetic reasons or in cases where surgical access is challenging.
  • Monitor Immune Status: In immunocompromised patients, closely monitor immune function and consider immunomodulatory strategies if indicated, although further clinical evidence is needed to establish specific protocols.
  • Follow-Up Care: Implement rigorous follow-up protocols post-treatment to monitor for recurrence and manage any potential side effects or complications effectively.
  • By integrating these recommendations, clinicians can provide comprehensive care tailored to the individual needs of patients with intraepidermal epithelioma of Jadassohn, balancing therapeutic efficacy with patient comfort and quality of life.

    References

    1 Konger RL, Malaviya R, Pentland AP. Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes. Biochimica et biophysica acta 1998. link00114-6) 2 Nakagawa S, Bang D, Takei Y, Jinno Y, Ueki H. A histologic study on the fate of intradermally implanted epidermal cells in guinea pigs: a new method for evaluation of skin allograft survival. The Journal of investigative dermatology 1987. link

    2 papers cited of 3 indexed.

    Original source

    1. [1]
      Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes.Konger RL, Malaviya R, Pentland AP Biochimica et biophysica acta (1998)
    2. [2]
      A histologic study on the fate of intradermally implanted epidermal cells in guinea pigs: a new method for evaluation of skin allograft survival.Nakagawa S, Bang D, Takei Y, Jinno Y, Ueki H The Journal of investigative dermatology (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG